A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
Public ClinicalTrials.gov record NCT06329791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Associated Symptoms of Dry Eye Disease (DED)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.
Study identification
- NCT ID
- NCT06329791
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 500 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2024 (Actual)
- Primary completion
- Dec 2024 (Estimated)
- Completion
- Nov 2025 (Estimated)
- Last update posted
- Sep 27, 2024
2024 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Eye Center | Chandler | Arizona | 85225 | — |
| Global Research Management, Inc | Glendale | California | 91204 | — |
| Eye Research Foundation | Newport Beach | California | 92663 | — |
| NVISION Clinical Research | Torrance | California | 90505 | — |
| Wyse Eyecare | Northbrook | Illinois | 60062 | — |
| Pankratz Eye Institute | Columbus | Indiana | 47203 | — |
| The Eye Care Institute/Butchertown Clinical Trials | Louisville | Kentucky | 40206 | — |
| Ophthalmology Associates | St Louis | Missouri | 63131 | — |
| NC Eye Associates | Apex | North Carolina | 27502 | — |
| Oculus Research, Inc. | Garner | North Carolina | 27529 | — |
| CORE | Shelby | North Carolina | 28150 | — |
| Scott & Christie and Associates, PC | Cranberry Township | Pennsylvania | 16066 | — |
| Advancing Vision Research (AVR) - Goodlettsville | Goodlettsville | Tennessee | 37072 | — |
| Total Eye Care | Memphis | Tennessee | 38119 | — |
| Advancing Vision Research (AVR) - Smyrna | Smyrna | Tennessee | 37167 | — |
| Piedmont Eye Center | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06329791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06329791 live on ClinicalTrials.gov.